• +A A A- Change screen font size
  • Keyboard navigation
  • Gray Default Change background color
  • See picture text

For healthy blood pressure and cholesterol levels

Benolea® proved similar to standard hypertensive therapy its ability to decrease blood pressure.

Blood pressure-reducing and lipid-lowering effect of Benolea® (EFLA®943) in stage-1 hypertension. Susalit, E., et al., Phytomedicine 2011, 18, 251-258.

Benolea® lowered blood pressure and LDL-cholesterol in adults with borderline hypertension.

Effect of Benolea® (EFLA®943) in adult twins with mild hypertension. Perrinjaquet-Moccetti, T., et al., Phytotherapy Research 2008, 22, 1239-1242.

Blood Pressure

A clinical trial carried out for 8 weeks in twins with borderline hypertension confirmed a dosage-dependent blood pressure reducing effect for Benolea®. Blood pressure changed significantly within twin pairs: mean systolic difference reached up to 6 mmHg between the control and the 500 mg dose group and up to 13 mmHg between the 500 mg and the 1000 mg dose group. Diastolic differences amount of 5 mmHg, respectively.

In the latest clinical study, Benolea® showed a comparable blood pressure reducing effect in people with mild elevated values (stage 1 hypertension) than a standard anti-hypertensive drug, Captopril. Benolea® also positively influenced the lipid profile of this population and was well tolerated. The blood pressure reduction in the Benolea® group after 8 weeks amounted to about 12 mmHg for systolic and 5 mmHg for diastolic blood pressure, respectively.

Decrease of systolic blood pressure from baseline

Cholesterol level

In a randomized, double-blind, double-dummy, active-controlled clinical trial with 232 volunteers aged 25 to 60 years with stage 1 hypertension (systolic blood pressure 140-159 mmHg, and/or diastolic blood pressure 90-99 mmHg) showed not only a blood pressure reduction but also a significant reduction of total cholesterol and triglycerides levels which was not observed in the anti-hypertensive drug Captopril group.

These findings echo the results of a preliminary study in twins, conducted in Germany which demonstrated a significant dose-dependent reduction of LDL (Low Density Lipoprotein) cholesterol for 500 mg and 1000 mg per day of Benolea® after 8 weeks. Increased levels of LDL are associated with atherosclerosis, and thus heart attack, stroke and peripheral vascular disease. For this reason, LDL cholesterol is often called ‘bad’ cholesterol.

Reduction of mean LDL-C concentration compared to baseline, after 4 and 8 weeks of intervention

READ MORE IN OUR PRODUCT FLYER

DOWNLOAD
x

Please fill out the form
to download the file